IJCM  Vol.2 No.3 , July 2011
Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel
ABSTRACT
This phase II study assessed the clinical response and short-term quality of life of patients receiving first-line chemotherapy with epirubicin-docetaxel combination for metastatic breast cancer. Thirty-one breast cancer patients were treated with epirubicin (75 mg/m2 for 15 minutes) followed one hour later by a one-hour infusion of docetaxel (75 mg/m2) q3w. EORTC QLQ-C30 and EORTC QLQ-BR23 forms were filled in at baseline, and at the second and eighth cycle of chemotherapy. The combination of epirubicin and docetaxel provided a high degree of clinical benefit. Clinical response was observed in 17 patients (55%), including five (16%) complete responses and 12 (39%) partial responses. Of responding and stable patients 23 (74%) maintained the same status for at least six months (clinical benefit). The mean survival time was 40.8 months. During the treatment the emotional functioning improved and the concerns about the future were relieved. Some aspects of quality of life were impaired, with slightly decreased physical and cognitive functioning, distress related to body image and hair loss, and adverse effects of chemotherapy. Overall, the global quality of life was maintained.

Cite this paper
nullJ. Korpela, P. Mali, A. Kaljonen and E. Salminen, "Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel," International Journal of Clinical Medicine, Vol. 2 No. 3, 2011, pp. 346-351. doi: 10.4236/ijcm.2011.23060.
References
[1]   N. Wilcken, R. Dear, “Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007”, European Journal of Cancer, Vol. 44, No. 15, 2008, pp. 2218-2225.

[2]   D. Ghersi, N. Wilcken, R.J. Simes, “A systematic review of taxane-containing regimens for metastatic breast cancer”, British Journal of Cancer, Vol. 93, No. 3, 2005, pp. 293-301.

[3]   A. Bottomley, L. Biganzoli, T. Cufer et al., “Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study”, Journal of Clinical Oncology, Vol. 22, No. 13, 2004, pp. 2576-2586.

[4]   P.A. Cassier, S. Chabaud, V. Trillet-Lenoir et al., “A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study”, Breast Cancer Research and Treatment, Vol. 109, No. 2, 2008, pp. 343- 350.

[5]   J.M. Nabholtz, C. Falkson, D. Campo, et al., “Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial”, Journal of Clinical Oncology, Vol. 21, No. 6, 2003, pp. 968-975.

[6]   J. Jassem, T. Pienkowski, A. Pluzanska, et al., “Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial”, Journal of Clinical Oncology, Vol. 19, No. 6, 2001, pp. 1707-1715.

[7]   G.W. Sledge, D. Neuberg, P. Bernardo, et al., “Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)”, Journal of Clinical Oncology, Vol. 21, No. 4, 2003, pp. 588-592.

[8]   H. Svensson, Z. Einbeigi, H. Johansson, T. Hatschek, Y. Brandberg, “Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)”, Breast Cancer Research and Treatment, Vol. 123, No. 3, 2010, pp. 785-793.

[9]   W. Yeo, T.S. Mok, K.K. Tse, et al. “Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer”, Anticancer Drugs, Vol. 13, No. 6, 2002, pp. 655-662.

[10]   J. Korpela, E. Salminen, “Neutropenic infections add significant costs to palliative chemotherapy in breast cancer”, Anticancer Research, Vol. 22, No. 2B, 2002, pp. 1337-1340.

[11]   E. Salminen, J. Korpela, M. Varpula, et al., “Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study”, Anticancer Drugs, Vol. 13, No. 9, 2002, pp. 925-929.

[12]   E. Salminen, K. Syvanen, J. Korpela, et al., “Docetaxel with epirubicin-investigations on cardiac safety”, Anticancer Drugs, Vol. 14, No. 1, 2003, pp. 73-77.

[13]   V. Dieras, “Review of docetaxel/doxorubicin combination in metastatic breast cancer”, Oncology (Williston Park), Vol. 11, No. 8, 1997, pp. 31-33.

[14]   E. Salminen, M. Bergman, S. Huhtala, E. Ekholm, “Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study”, Journal of Clinical Oncology, Vol. 17, No. 4, 1999, pp. 1127-31.

[15]   A.B. Miller, B. Hoogstraten, M. Staquet, A. Winkler, “Reporting results of cancer treatment”. Cancer, Vol. 47, No. 1, pp. 207-214.

[16]   N.K. Aaronson, S. Ahmedzai, B. Bergman, et al., “The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology”, Journal of the National Cancer Institute, Vol. 85, No. 5, 1993, pp. 365-376.

[17]   M.A. Sprangers, M. Groenvold, J.I. Arraras, et al., “The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study”, Journal of Clinical Oncology, Vol. 14, No. 10, 1996, pp. 2756-2768.

[18]   D. Osoba, G. Rodrigues, J. Myles, B. Zee, J. Pater, “Interpreting the significance of changes in health-related quality-of-life scores”, Journal of Clinical Oncology, Vol. 16, No. 1, 1998, pp. 139-144.

[19]   A.J. Ramirez, K.E. Towlson, M.S. Leaning, M.A. Richards, R.D. Rubens, “Do patients with advanced breast cancer benefit from chemotherapy?”, British Journal of Cancer, Vol. 78, No. 11, 1998, pp. 1488-1494.

[20]   F.S. van Dam, S.B. Schagen, M.J. Muller, et al., “Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy”, Journal of the National Cancer Institute, Vol. 90, No. 3, 1998: pp. 210-218.

[21]   S.A. Castellon, P.A. Ganz, J.E. Bower, L. Petersen, L. Abraham, G.A. Greendale, “Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen”, Journal of Clinical and Experimental Neuropsychology, Vol. 26, No. 7, 2004, pp. 955-969.

[22]   J. Vardy, J.S. Wefel, T. Ahles, I.F. Tannock, S.B. Schagen, “Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop”, Annals of Oncology, Vol. 19, No. 4, 2008, pp. 623-629.

[23]   L. Hakamies-Blomqvist, M. Luoma, J. Sjostrom, et al., “Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group”, European Journal of Cancer, Vol. 36, No. 11, 2000, pp. 1411-1417.

[24]   A. Bottomley, P. Therasse, “Quality of life in patients undergoing systemic therapy for advanced breast cancer”, The Lancet Oncology, Vol. 3, No. 10, 2002, pp. 620-628.

[25]   G. Fountzilas, U. Dafni, M.A. Dimopoulos, et al., “A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study”, Breast Cancer Res Treat, Vol. 115, No. 1, 2009, pp. 87-99.

[26]   L. Hakamies-Blomqvist, M.L. Luoma, J. Sjostrom, et al.,“Timing of quality of life (QoL) assessments as a source of error in oncological trials”, Journal of Advanced Nursing, Vol. 35, No. 5, 2001, pp. 709-716.

[27]   P. Hopwood, A. Harvey, J. Davies, et al., “Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee”, European Journal of Cancer, Vol. 34, No. 1, 1998, pp. 49-57.

[28]   P. Hopwood, R.J. Stephens, D. Machin. “Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial”, Quality of Life Research, Vol 3, No. 5, 1994, pp. 339-352.

[29]   C.C. Gotay, J. Lipscomb, C.F. Snyder, “Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase”, Journal of the National Cancer Institute, Vol. 97, No. 21, 2005, pp. 1568-1574.

 
 
Top